The global Pediatric Obesity Management Market is expected to garner a market value of USD 3.2 Billion in 2023 and is expected to accumulate a market value of USD 4.74 Billion by registering a CAGR of 4% in the forecast period 2023 to 2033. The market for Pediatric Obesity Management registered a CAGR of 3% in the historical period 2018 to 2022.
The Pediatric Obesity Management market is a segment of the healthcare industry that deals with the effective management of the condition. The Pediatric Obesity Management market offers a range of products and services for its effective management and treatments including medications such as Lifestyle modifications, Behavioral therapy, Medications, and Bariatric surgery.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 3.2 Billion |
| Anticipated Forecast Value (2033) | USD 4.74 Billion |
| Projected Growth Rate (2023 to 2033) | 4% CAGR |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
According to market research and competitive intelligence provider, Future Market Insights- the market for Pediatric Obesity Management reflected a value of 3% during the historical period, 2018 to 2022. During this period, the demand for treatment for Pediatric Obesity increased, driven by factors such as an increase in the prevalence of pediatric obesity, rising awareness about the health risks associated with obesity, and the development of new and innovative treatment options.
Moving forward, it is expected that the pediatric obesity management market will continue to grow. Factors such as increasing government initiatives and funding towards obesity prevention and management programs, rising disposable income, and growing healthcare infrastructure are expected to further boost the growth of the market. Additionally, there is a trend towards developing new and innovative treatment options for pediatric obesity, such as pharmacological treatments and bariatric surgery.
Overall, the demand for pediatric obesity management is expected to increase in the forecast period of 2023 to 2033, driven by a growing need for effective solutions to prevent and manage pediatric obesity. The market is likely to continue to be segmented based on treatment type, with lifestyle modifications remaining the most common treatment option, followed by medications and surgery. However, new and innovative treatment options are expected to continue to emerge, expanding the range of available treatment options for pediatric obesity management.
Furthermore, in the years to come, increasing focus by government organizations and private agencies like WHO and pharmaceutical companies are creating awareness of Pediatric Obesity Management, fuelling the market growth. Thus, the market for Pediatric Obesity Management is expected to register a CAGR of 4% in the forecast period 2023 to 2033.
Growing advancements in diagnostic and treatment options to push the market growth
The global Pediatric Obesity Management market is primarily driven by an increased prevalence of Pediatric Obesity, which is driving the demand for effective treatments. The prevalence of pediatric obesity is increasing globally, with more and more children and adolescents becoming overweight or obese. This has created a need for effective obesity management solutions.
Both the United kingdom and USA are facing an obesity crisis, as revealed by recent surveys. In the United kingdom, the Health Survey for England 2019 found that 28% of adults were classified as obese, and 36.2% were overweight but not yet obese. The Covid-19 pandemic contributed to a rise in sedentary lifestyles, exacerbating the obesity epidemic. Similarly, the USA is also experiencing an increase in obesity. According to the 2017 to 2018 National Health and Nutrition Examination Survey (NHANES), 30.7% of adults were overweight, 42.4% were obese, and 9.2% suffered from severe obesity.
Due to the growing prevalence, there is a growing awareness about the health risks associated with pediatric obesity, such as type 2 diabetes, cardiovascular disease, and other chronic conditions. This has led to increased efforts to prevent and treat obesity in children and adolescents, which is also contributing to the growth of the market.
There is a trend towards developing new and innovative treatment options for pediatric obesity. For example, there has been a growing interest in the use of pharmacological treatments and bariatric surgery for pediatric obesity, which is expanding the range of available treatment options. Additionally, the increasing government initiatives and funding towards obesity prevention and management programs, rising disposable income, and growing healthcare infrastructure are expected to further boost the growth of the pediatric obesity management market.
Overall, the pediatric obesity management market is expected to continue to grow in the coming years, driven by increasing demand for effective solutions to prevent and manage pediatric obesity.
For instance, in October 2022, Eli Lilly's Mounjaro (tirzepatide) was granted Fast Track designation by the USA FDA in October for its potential use as a treatment for obesity. The drug was previously approved in May for treating type 2 diabetes mellitus. Mounjaro has shown comparable efficacy rates to surgical procedures such as sleeve gastrectomies, making it the first weight loss drug of its kind. Other treatments, including Novo Nordisk's CagriSema (a combination of semaglutide and cagrilintide), are expected to follow suit after producing promising Phase II results.
Overall, the pediatric obesity management market is expected to continue to grow in the coming years, driven by increasing demand for effective solutions to prevent and manage pediatric obesity.
Expensive Cost of Treatment to restrict Market Growth
One of the biggest challenges in managing pediatric obesity is the lack of awareness about the condition and its health consequences. Many parents and caregivers may not recognize the signs of obesity in children, and healthcare providers may not always prioritize obesity management in their treatment plans.
While there are several treatment options available for pediatric obesity, there is still a need for more effective and innovative solutions. The current treatment options may not work for all children, and there is a lack of consensus on the most effective approach to treating pediatric obesity.
Furthermore, the cost of treating pediatric obesity can be a barrier for many families, especially those who are low-income or underinsured. Medications and surgeries can be expensive, and insurance coverage for these treatments may be limited.
Increasing Healthcare Spending Shaping Landscape for Pediatric Obesity Management in South & East Asia
Pediatric Obesity is becoming increasingly prevalent in the South & East Asia region. The South & East Asia region is home to a significant proportion of the global population, and the prevalence of pediatric obesity in the region has been steadily increasing in recent years. The region is diverse, and there are differences in cultural norms, dietary habits, and lifestyle patterns across different countries, which can impact the prevalence and management of pediatric obesity.
In the region, the market for pediatric obesity management is expected to grow in the coming years, driven by factors such as a growing awareness of the health risks associated with pediatric obesity, increasing government initiatives to address the issue, and the development of new and innovative treatment options.
Healthcare spending is increasing in many countries in the region, which is expected to drive demand for Pediatric Obesity Managements. As individuals become more affluent and more willing to spend on healthcare, demand for treatments is likely to increase.
Increasing Focus on Technological advancements Shaping Landscape for Pediatric Obesity Management in North America
North America is anticipated to acquire a market share of about 40% in the forecast period. This growth is attributable to the high prevalence of Pediatric Obesity in North America which has led to a strong demand for new treatments. North America has one of the highest rates of pediatric obesity in the world, with approximately one in five children considered obese. This high prevalence has led to an increased demand for effective solutions to manage and prevent pediatric obesity.
Additionally, North America has a well-developed healthcare infrastructure, along with a high level of research and development, significant investment, and a supportive regulatory environment. overnments in North America are increasingly investing in initiatives to address pediatric obesity, including public education campaigns, policies to promote healthy eating and physical activity, and funding for research and treatment.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
Preventive medications to hold a significant share and push market growth
According to various reports and studies, currently, the oral route of administration is the most commonly used and is likely to account for a significant share of the market. This is because oral medications and supplements are relatively easy to administer, and they have been widely used for many years to manage pediatric obesity.
In addition to oral medications and supplements, there is growing interest in other routes of administration, such as injectable and transdermal formulations. These routes of administration offer certain advantages over oral medications, such as improved compliance and reduced gastrointestinal side effects.
Hospital Pharmacies to take the lead and drive market growth
According to the FMI analysis, Hospital pharmacies account for the largest market share. The requirement for several hospital stays and visits during the Pediatric Obesity Management treatment facilitates the growth of this segment. Majority of the serious diseases involving the nervous system are treated in hospitals, and with the availability of trained medical personnel, it is simpler to control an individual's health more correctly.
Key players in the market include companies such as Pfizer Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc., AstraZeneca, Herbalife Ltd., Apollo Endosurgery, Ethicon, Inc., Takeda Pharmaceutical Company, VIVUS Inc., Currax Pharmaceuticals LLC, along with healthcare providers and technology companies among other global players.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 3.2 Billion |
| Market Value in 2033 | USD 4.74 Billion |
| Growth Rate | CAGR of 4% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered | Drug Class, Route of Administration, Distribution Channel, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Rest of Latin America, Germany, United Kingdom, France, Spain, Italy, Rest of Europe, Malaysia, Singapore, China, India, Thailand, Rest of South Asia, Gulf Cooperation Council, Japan, South Korea, Australia, New Zealand, GCC countries, South Africa, Israel, Rest of Middle East and Africa(MEA) |
| Key Companies Profiled | Pfizer Inc.; F. Hoffmann-La Roche Ltd; GlaxoSmithKline plc.; AstraZeneca, Herbalife Ltd.; Apollo Endosurgery; Ethicon, Inc.; Takeda Pharmaceutical Company; VIVUS Inc.; Currax Pharmaceuticals LLC |
| Customization | Available Upon Request |
The market is valued at USD 3.2 billion in 2023.
In the historical period 2018 to 2022, the market grew at a CAGR of 3%.
The market is estimated to secure a valuation of USD 4.74 Billion in 2033.
Through 2033, the pediatric obesity management market is projected to continue to expand at a CAGR of 4%.
Costly treatment to limit pediatric obesity management market growth.
| Market Size, 2024 | USD 14,511 million |
|---|---|
| Projected Market Size, 2034 | USD 48,396 million |
| Value-based CAGR (2024 to 2034) | 12.8% |
| Estimated Market Share in 2023 | USD 2,095.6 million |
|---|---|
| Forecasted Market Size by 2033 | USD 3,494.5 million |
| Projected Market Growth Rate from 2023 to 2033 | 5.2% CAGR |
Explore Therapy Area Insights
View Reports
Pediatric Obesity Management Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
